PML-RARA, often known as promyelocytic leukemia/retinoic acid receptor alpha, is an aberrant fusion gene sequence. Chromosome translocation refers to a specific rearrangement of genetic information from two distinct chromosomes that are connected to a certain kind of leukemia. Can APML...
PML-RARA, often known as promyelocytic leukemia/retinoic acid receptor alpha, is an aberrant fusion gene sequence. Chromosome translocation refers to a specific rearrangement of genetic information from two distinct chromosomes that are connected to a certain kind of leukemia.
Patients between the ages of 20 and 50 are the patients most likely to have the condition diagnosed. When given therapy, people with APL frequently experience a normal or almost normal quality of life.
The maturation is stopped at the promyelocyte stage when PML-RAR takes control of RARE sites and inhibits the activation of transcription by physiological ligands. Disruption of PML NBs has been linked to several cellular events that result in the oncogenic phenotype of APL.
Normal Performance. The retinoic acid receptor, alpha (RAR) gene codes for the production of a transcription factor.
The median age of those diagnosed with acute promyelocytic leukemia is 47 years old.
Arsenic trioxide is another treatment option for APML patients. This is injected into a vein via drip every day. Arsenic trioxide and ATRA induction typically last 5 to 6 weeks.
The PML-RARA fusion gene or its transcripts, which are RNA copies that the cell makes from the aberrant gene sequence of DNA, are found through testing. The PML-RARA anomaly contributes to the confirmation of the APL diagnosis. Additionally, testing can guide APL therapy and track potentially catastrophic minimum residual disease.
90% of patients who had ATRA-chemotherapy survived for two years without developing APL. However, complications from bleeding or infections frequently result in death if APL is not treated. Anyone exhibiting APL symptoms should get in touch with their doctor immediately.
R/R APL has been treated with a variety of regimens, including ATRA, anthracyclines, ATO, high-dose ARA-C, and GO. The induction regimen and whether the relapse happened during treatment influence the choice of chemotherapy.
|Test Type||Acute Promyeloid Leukemia (APML) - PML-RARA|
Acute Promyeloid Leukemia (APML) - PML-RARA (Pathology Test)
Within 24 hours*
Early check ups are always better than delayed ones. Safety, precaution & care is depicted from the several health checkups. Here, we present simple & comprehensive health packages for any kind of testing to ensure the early prescribed treatment to safeguard your health.